Researchers found use of antimicrobial ceftriaxone was linked to increased risk of vancomycin-resistant enterococci bloodstream infection, according to a study published in Infection Control and Hospital Epidemiology.
Researchers assessed the outcomes of all patients admitted to University of Alabama at Birmingham Medical Center from 2005 to 2008 to determine whether antimicrobial use was associated with increased risk or incidence of VRE bloodstream infections.
They found prior-month usage of the antibiotics piperacillin-tazobactam, ceftazidime, cefepime, cefazolin or vancomycin was not predictive of VRE bloodstream infection. However use of antimicrobial ceftriaxone in the prior month was associated with increased incidence of VRE bloodstream infection. Researchers concluded lower use of this type of antimicrobial may improve infection prevention efforts.
Researchers assessed the outcomes of all patients admitted to University of Alabama at Birmingham Medical Center from 2005 to 2008 to determine whether antimicrobial use was associated with increased risk or incidence of VRE bloodstream infections.
They found prior-month usage of the antibiotics piperacillin-tazobactam, ceftazidime, cefepime, cefazolin or vancomycin was not predictive of VRE bloodstream infection. However use of antimicrobial ceftriaxone in the prior month was associated with increased incidence of VRE bloodstream infection. Researchers concluded lower use of this type of antimicrobial may improve infection prevention efforts.
Related Articles on Antimicrobial Stewardship:
Antimicrobial Stewardship Programs Reduce CDI Rates, Healthcare Costs
Antimicrobial Resistance to Common UTI Drug Increases 5-Fold
FDA Takes Steps to Foster Judicious Antimicrobial Use